Alliance Global analyst Scott Henry lowered the firm's price target on Tenon Medical to $2.25 from $2.50 and keeps a Buy rating on the shares. The firm notes Tenon Medical reported Q1 earnings that were within the range of its expectations. Alliance Global points out that Q1 revenue was slightly below its estimate, the key focus will be on the ongoing launch of SImmetry+ and that the cash balance suggests a runway into Q3 2026.
